Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-07-18
2006-07-18
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07078038
ABSTRACT:
An isolated and purified human immunodeficiency virus type 1 (HIV-1) mutant gp120 envelope glycoprotein containing an amino acid mutation in position112which contains replacement of W with S, I, or F, wherein the numbering scheme is based upon the molecular clone HxBc2.
REFERENCES:
patent: 5792459 (1998-08-01), Haigwood
patent: 2003/0104577 (2003-06-01), Lingappa et al.
Hansen, J. E., et al., 1996, “Prediction of the secondary structure of HIV-1 gp120.”, PROTEINS: Structure, Function, and Genetics 25:1-11.
Gross, I., et al., 1997, “In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus.”, Eur. J. Biochem. 249:592-600.
Vlasuk, G.P., et al., 1989, “Purification and characterization of human immunodeficiency virus (HIV) core precursor (p55) expressed inSaccharomyces cerevisiae.”, J. Biol. Chem. 264(20):12106-12112.
Quinones-Mateu, M. E. et al.: “Molecular characterization of human imunodeficiency virus type l isolates from Venezuela.” AIDS Research and Human Retroviruses, vol. 11, No. 5, 1995, pp. 605-616.
Misse D. et al. “Dissociation of the CD4 and CXCR4 binding properties of human inununodeficiency virus type 1 gpl20 by deletion of the first putative alpha-helical conserved structure” Journal of Virology, vol. 72, No. 9, Sep. 1998, pp. 7280-7288.
Willey, R.L. et al.: “Amino acid substitutions In the human inununodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.” Journal of Virology, vol. 68, No. 7, Jul. 1994, pp. 4409-4419.
Thali, M. et al.: “Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human inmiunodeficiency virus type 1 gp120 envelope glycoprotein.” Journal of Virology, vol. 66, No. 9, Sep. 1992, pp. 5635-5641.
Cordonnier, A. et al.: “Single amino-acid changes in HIV envelope affect viral tropism and receptor binding.” NATURE, vol. 340, Aug. 1989, pp. 571-574.
Korber, B.T.M. et al.: “Genetic differences between blood- and brain-derived viral sequences from huamn immunodeficiency virus type 1-infected patients: evidience of conserved elements in the V3 region of the envelope protein of brain-derived sequences.” Journal of Virology, vol. 68, No. 11, Nov. 1994, pp. 7467-7481.
Lund, O. et al.: “Inhibition of HIV type 1 infectivity by coexpression of a wild-type and a defective glycoprotein 120.” AIDS Research and Human Retroviruses, vol. 14, No. 16, Nov. 1998, pp. 1445-1450.
Kwong, P. D. et al.: “Structure of an HIV GP120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.” NATURE, vol. 393, Jun. 1998, pp. 648-659.
Cerutti Martine
Veas Francisco
Institut de Recherche pour le Developpement (I.R.D.)
Nixon & Vanderhye P.C.
Parkin Jeffrey S.
LandOfFree
Gp120 mutants and biological applications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gp120 mutants and biological applications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gp120 mutants and biological applications will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3577123